Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2020, Vol. 25 ›› Issue (7): 835-840.doi: 10.12092/j.issn.1009-2501.2020.07.018

Previous Articles    

Four dimensions of receiving overseas clinical trial data about drug and medical devices

JIANG Haihong 1,2, LI Xiao 3, LIU Yang 1   

  1. 1 School of Medical Instrument Shanghai University of Medical & Health Science, Shanghai 201318, China; 2 Law School of Shanghai University of Finance and Economics, Shanghai 200433, China; 3 National Medical Products Administration Institute of Executive Development, Beijing 100073, China
  • Received:2020-02-24 Revised:2020-06-15 Online:2020-07-26 Published:2020-07-31

Abstract: China has started to accept the overseas clinical trial data about drug and medical devices, and the data in accordance with the requirements can be used to register in China. To do this work well, we should consider four key dimensions: data acceptance principle, data quality and reliability, data evaluation usability and data international difference. Among them, the authenticity, integrity, accuracy and traceability of data are the main factors to determine the quality reliability of data. Receiving data from overseas clinical trials about drug and medical devices will be conducive to the establishment of international mutual recognition system for clinical trial data, and to enhance the importance of data management in domestic clinical trials, and to promote the formation of quality management system on clinical trial data.

Key words: drugs, medical devices, overseas clinical trials, quality of data management

CLC Number: